EG 427, a biotech company developing targeted genetic medicines for neurological conditions, secured €27 million in Series B funding. The round was co-led by Andera Partners and Bpifrance, with participation from SCI Ventures and existing investors. The funding will primarily support the Phase 1b/2a clinical trial of EG110A, a treatment for neurogenic detrusor overactivity (NDO) in spinal cord injury patients, and further development of EG 427’s HERMES vector technology platform.
This investment marks a significant step forward for the treatment of neuro-urological disorders, an area with limited therapeutic advances and high healthcare costs. The clinical trial of EG110A offers the potential for a novel treatment approach for NDO, a debilitating condition affecting bladder control. Success in this trial would not only validate EG 427’s technology but could also pave the way for its application in other neuro-urological conditions currently lacking effective treatment options. This represents a critical opportunity to improve the quality of life for a substantial patient population.
The €27 million investment will enable EG 427 to generate crucial safety and early efficacy data for EG110A, a non-replicating HSV-1 vector designed to silence overactive bladder signals without impacting voiding function. This funding also allows the company to broaden its pipeline by leveraging its proprietary HERMES technology, which boasts targeted delivery, potential for repeated dosing, and cost-effective production compared to AAV-based vectors. These advantages position EG 427 to offer potentially more effective and sustainable therapeutic solutions.
This successful funding round signals growing confidence in EG 427’s innovative approach to neuro-urological diseases. Positive clinical trial results for EG110A could significantly impact the treatment landscape for NDO and related conditions. Furthermore, advancement of the HERMES platform could lead to the development of new genetic medicines for a range of neurological disorders, ultimately benefiting patients and reducing the burden on healthcare systems.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
